What Follistatin-315 is
Follistatin-315 is another follistatin isoform discussed around activin and myostatin-pathway biology in muscle-regulation contexts.
Follistatin-315 is grouped under Fitness + Recovery on PeptideFactCheck because it shows up in the same muscle-growth and myostatin-suppression conversations as follistatin-344.
The useful starting point is to separate the molecule itself from the internet story around it. It shows up in the same muscle-growth and myostatin-suppression conversations as follistatin-344.
Why people keep looking it up
It shows up in the same muscle-growth and myostatin-suppression conversations as follistatin-344.
Follistatin-315 is another follistatin isoform discussed around activin and myostatin-pathway biology in muscle-regulation contexts.
Follistatin-315 tends to stay in the conversation because it touches a familiar public theme: myostatin pathway, muscle regulation, and activin binding. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Mostly pathway extrapolation, not clean human performance evidence.
The usual body-composition claims are not backed by strong product-level human evidence in this seed set.
Most support remains pathway-driven and preclinical.
Why this page carries the current tier: Mostly pathway extrapolation, not clean human performance evidence.
The current seed trail for Follistatin-315 is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Large claims in this area often ignore how broad and consequential TGF-beta family signaling is.
No FDA-approved follistatin-315 peptide product is represented in this seed set.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Follistatin-315. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Clinical trial snapshot
The current ClinicalTrials.gov intervention query for Follistatin-315 returns 0 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
No linked intervention records were returned by the current ClinicalTrials.gov query terms for this page.
Literature snapshot
The current PubMed query for Follistatin-315 returns 16 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.